期刊
NEUROMUSCULAR DISORDERS
卷 26, 期 1, 页码 7-15出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.nmd.2015.10.003
关键词
Gene panel; Myopathy; Next-generation sequencing
资金
- Folkhalsan Research Foundation
- Jane and Aatos Erkko Foundation
- Association Francaise contre les Myopathies [SB/CP2013-0106]
- Academy of Finland [138491]
- Sigrid Juselius Foundation
- Liv och Halsa Foundation
- Tampere University Hospital Research Funds
- Academy of Finland (AKA) [138491, 138491] Funding Source: Academy of Finland (AKA)
Mutations in more than 100 different genes are known to cause hereditary primary myopathies. In patients with less distinct phenotypes several genes may have to be sequenced in order to make the correct diagnosis. The large number of possible candidate genes and overlapping phenotypes, as well as an enormous size of some of the genes such as DMD, TTN and NEB, constitute difficult challenges for molecular genetic diagnostics using conventional sequencing. Molecular characterization is nevertheless important for the final diagnosis and accurate management of the diseases. Targeted next-generation sequencing is a rapid and cost-effective method to sequence large numbers of genes simultaneously. We developed a targeted next-generation sequencing assay, MyoCap, for the coding exons and UTRs of 180 myopathy related genes including 42 novel genes that have not yet been associated with myopathies. DNA samples of four controls with known mutations and 61 patients negative for previous candidate gene approaches were sequenced. The genetic defect was totally or partly clarified in 21 patients with nine of them having potential disease-causing mutations in TTN. MyoCap provides higher read depth and coverage with lower price in the myopathy related genes compared to the whole exome sequencing and is thus very suitable for diagnostic use. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据